Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
21 Ottobre 2024 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that leading HAE experts
will present two posters at the American College of Allergy,
Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Boston,
Massachusetts on October 25, 2024.
Dr. Aleena Banerji, M.D., Associate Professor of Medicine at
Harvard Medical School and Clinical Director of the Allergy and
Immunology Unit at Massachusetts General Hospital, will present new
quality of life data from initial results from the Phase 1b/2 trial
of navenibart (STAR-0215) in a presentation of a poster titled
“STAR-0215 Induces Rapid Improvements of Quality of Life in HAE
Patients in the ALPHA-STAR Trial.” The presentation will take place
in Exhibit Hall A on Friday, October 25 at 3:30pm EST.
Astria sponsored additional quality of life research in people
living with HAE that will be presented by Dr. Donald Levy, M.D.,
Health Sciences Professor of Medicine in the Division of Basic and
Clinical Immunology at the University of California at Irvine. Dr.
Levy will present a poster titled “Quality of Life and Burden of
Disease in Patients with Hereditary Angioedema and their
Caregivers” in Exhibit Hall A on Friday, October 25 at 3:45pm
EST.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunologic diseases. Our lead
program, navenibart (STAR-0215), is a monoclonal antibody inhibitor
of plasma kallikrein in clinical development for the treatment of
hereditary angioedema. Our second program, STAR-0310, is a
monoclonal antibody OX40 antagonist in preclinical development for
the treatment of atopic dermatitis. Learn more about our company on
our website, www.astriatx.com, or follow us on X and Instagram
@AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021639207/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Gen 2024 a Gen 2025
